Physician profile
John P Winikates
NPI 1386697712
$1,759.63
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $245 · 2022: $16.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $317.65 | 2019-2020 | |
| Ucb, INC. | $193.74 | 2019 | |
| Emd Serono, INC. | $185.42 | 2019-2020 | |
| Biogen, INC. | $142.68 | 2019-2020 | |
| Genzyme Corporation | $134.35 | 2019-2020 | |
| Eisai INC. | $125.92 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $122.70 | 2019 | |
| Abbvie INC. | $53.52 | 2019 | |
| Pfizer INC. | $39.34 | 2019 | |
| Genentech USA, INC. | $38.62 | 2019 | |
| Adamas Pharmaceuticals, INC. | $37.53 | 2019 | |
| Greenwich Biosciences, INC. | $37.27 | 2019 | |
| Acadia Pharmaceuticals INC | $35.27 | 2019-2020 | |
| Amgen INC. | $32.17 | 2020 | |
| Livanova USA, INC. | $29.73 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $27.22 | 2019-2020 | |
| Allergan, INC. | $27.21 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $26.93 | 2020 | |
| Lilly USA, LLC | $23.29 | 2019 | |
| Upsher-Smith Laboratories LLC | $22.95 | 2019 | |
| Harmony Biosciences LLC | $21.40 | 2020 | |
| Alexion Pharmaceuticals, INC. | $17.11 | 2019 | |
| Mdd US Operations, LLC | $16.68 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $15.98 | 2019 | |
| Neurocrine Biosciences, INC. | $12.71 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.17 | 2019 | |
| Sk Life Science, INC. | $11.07 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Winikates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.